Genta Genasense NDA In Myeloma Or Leukemia Slated For Year-End Filing
Genta is shifting its Genasense development focus to multiple myeloma and chronic lymphocytic leukemia with the goal of submitting an NDA for one of the oncology indications by year-end
You may also be interested in...
The favorable toxicity profile of Lilly's oncologic Alimta outweighs uncertain survival benefits in the second-line treatment of non-small cell lung cancer, FDA's Oncologic Drugs Advisory Committee agreed July 27
Aventis will participate in Genta's meeting with FDA following the withdrawal of the new drug application for Genasense
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011